908 filings
Page 5 of 46
4
Carmen Jeffrey Del
12 Dec 23
CATALYST PHARMACEUTICALS / Carmen Jeffrey Del ownership change
5:00pm
144
Tierney David S
12 Dec 23
Notice of proposed sale of securities
2:21pm
4
CPRX
Catalyst Pharmaceuticals Inc
11 Dec 23
CATALYST PHARMACEUTICALS / Richard J Daly ownership change
5:00pm
144
Alicia Grande
11 Dec 23
Notice of proposed sale of securities
2:57pm
144
Alicia Grande
11 Dec 23
Notice of proposed sale of securities
12:54pm
4
CPRX
Catalyst Pharmaceuticals Inc
8 Dec 23
CATALYST PHARMACEUTICALS / GARY INGENITO ownership change
5:00pm
S-8
CPRX
Catalyst Pharmaceuticals Inc
8 Dec 23
Registration of securities for employees
4:31pm
S-8
CPRX
Catalyst Pharmaceuticals Inc
8 Dec 23
Registration of securities for employees
4:31pm
144
Alicia Grande
8 Dec 23
Notice of proposed sale of securities
4:14pm
4
CPRX
Catalyst Pharmaceuticals Inc
7 Dec 23
CATALYST PHARMACEUTICALS / Steve Miller ownership change
5:00pm
8-K
CPRX
Catalyst Pharmaceuticals Inc
7 Dec 23
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
4:30pm
144
Gary Ingenito
6 Dec 23
Notice of proposed sale of securities
12:48pm
144
CPRX
Catalyst Pharmaceuticals Inc
5 Dec 23
Notice of proposed sale of securities
4:46pm
8-K
CPRX
Catalyst Pharmaceuticals Inc
8 Nov 23
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
4:35pm
10-Q
2023 Q3
CPRX
Catalyst Pharmaceuticals Inc
Quarterly report
8 Nov 23
4:06pm
8-K
CPRX
Catalyst Pharmaceuticals Inc
3 Nov 23
New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio
4:30pm
8-K
CPRX
Catalyst Pharmaceuticals Inc
27 Oct 23
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
4:30pm
8-K
CPRX
Catalyst Pharmaceuticals Inc
20 Oct 23
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
4:31pm
8-K
CPRX
Catalyst Pharmaceuticals Inc
13 Oct 23
The sNDA Seeks to Increase the Indicated Maximum Daily Dose for FIRDAPSE to 100mg for the Treatment of Lambert-Eaton Myasthenic Syndrome
8:15am
8-K
CPRX
Catalyst Pharmaceuticals Inc
25 Sep 23
Regulation FD Disclosure
5:46pm